Quick Answer
Corbus Pharmaceuticals Holdings, Inc. reported Net Income Loss of -$78.54 million for the year ending 2025.
- Corbus Pharmaceuticals Holdings, Inc. showed a decrease of -95.3% in Net Income Loss from 2024 to 2025.
- This data is from Corbus Pharmaceuticals Holdings, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2013: -$59.6 thousand | Q1 2014: -$116.0 thousand | Q2 2014: -$504.6 thousand | Q3 2014: -$659.6 thousand | Q1 2015: -$1.54 million | Q2 2015: -$2.56 million | Q3 2015: -$2.25 million | Q1 2016: -$2.89 million | Q2 2016: -$4.19 million | Q3 2016: -$5.35 million | Q4 2016: -$7.57 million | Q1 2017: -$7.47 million | Q2 2017: -$7.30 million | Q3 2017: -$6.97 million | Q4 2017: -$10.69 million | Q1 2018: -$11.70 million | Q2 2018: -$12.07 million | Q3 2018: -$14.60 million | Q1 2019: -$26.23 million | Q2 2019: $2.15 million | Q3 2019: -$20.79 million | Q1 2020: -$29.66 million | Q2 2020: -$38.11 million | Q3 2020: -$34.90 million | Q1 2021: -$16.07 million | Q2 2021: -$17.14 million | Q3 2021: -$2.18 million | Q1 2022: -$9.44 million | Q2 2022: -$13.25 million | Q3 2022: -$8.78 million | Q1 2023: -$17.74 million | Q2 2023: -$8.78 million | Q3 2023: -$10.05 million | Q1 2024: -$6.90 million | Q2 2024: -$10.00 million | Q3 2024: -$13.78 million | Q1 2025: -$16.98 million | Q2 2025: -$17.66 million | Q3 2025: -$23.34 million.
- Over the full 13 years of available data (2013 to 2025), Corbus Pharmaceuticals Holdings, Inc.'s Net Income Loss has declined by 12,938.4%.
- Historical annual values: Fiscal year 2025: -$78.54 million | Fiscal year 2024: -$40.21 million | Fiscal year 2023: -$44.60 million | Fiscal year 2022: -$42.35 million | Fiscal year 2021: -$45.64 million | Fiscal year 2020: -$111.27 million | Fiscal year 2019: -$71.45 million | Fiscal year 2018: -$55.67 million | Fiscal year 2017: -$32.42 million | Fiscal year 2016: -$20.00 million | Fiscal year 2015: -$8.85 million | Fiscal year 2014: -$2.54 million | Fiscal year 2013: -$602.4 thousand.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: